Statistics from Altmetric.com
We have previously reported that colorectal cancer (CRC) liver metastases from patients, who had received the selective cyclooxygenase 2 (COX-2) inhibitor rofecoxib (Vioxx) 25 mg daily for a mean period of 26 days, had a 31% lower mean microvessel density compared with tumours from individuals who had received placebo only.1 These data suggest that one mechanism of action of rofecoxib in human CRC liver metastases might be inhibition of angiogenesis. Therefore, we investigated the potential antiangiogenic activity of rofecoxib in human CRC liver metastases by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), before and after treatment with oral rofecoxib 25 mg daily for 28 days. As short term treatment of rats with the selective COX-2 inhibitor celecoxib is associated with an increase in serum levels of the endogenous antiangiogenic factor endostatin,2 we also measured serum levels of endostatin and the proangiogenic factor vascular endothelial growth factor (VEGF), at the same time as DCE-MRI.
Patients undergoing liver resection of CRC liver metastases were enrolled if diagnostic MRI identified a single metastasis greater than 1.5 cm …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.